Efficacy of moxidectin 2.5% and imidacloprid 10% in the treatment of ocular thelaziosis by Thelazia callipaeda in naturally infected dogs
Domenico Otranto, Vito Colella, Giuseppe Crescenzo, Fabrizio Solari Basano, Roberto Nazzari, Gioia Capelli, Gabriele Petry, Roland Schaper, Matthias Pollmeier, Egidio Mallia, Filipe Dantas-Torres, Riccardo Paolo Lia
VETERINARY PARASITOLOGY | ELSEVIER SCIENCE BV | Published : 2016
Thelazia callipaeda (Spirurida, Thelaziidae) has been documented as agent of ocular infection in domestic animals (dogs and cats), wildlife (e.g., foxes, hares, rabbits), and humans. In the last two decades, this parasitosis has been increasingly reported in several European countries. Both adult and larval stages of the eyeworm are responsible for symptoms ranging from mild (e.g., lacrimation, ocular discharge, epiphora) to severe (e.g., conjunctivitis, keratitis, and corneal opacity or ulcers). The present study evaluated the clinical efficacy and safety of imidacloprid 10% and moxidectin 2.5% spot on (Advocate(®), Bayer Animal Health) in comparison to milbemycin oxime/praziquantel tablets..View full abstract
This research was supported by Bayer Animal Health GmbH, Leverkusen, Germany.